A review of the latest research on Mpro targeting SARS-COV inhibitors

Huihui Yang; Jinfei Yang

doi:10.1039/d1md00066g

A review of the latest research on M^pro targeting SARS-COV inhibitors

RSC Med Chem. 2021 Apr 14;12(7):1026-1036. doi: 10.1039/d1md00066g. eCollection 2021 Jul 21.

Authors

Huihui Yang¹, Jinfei Yang^{2

1}

Affiliations

¹ Medical School Institute of Reproductive Medicine, Nantong University Nantong 226019 China jfyang@ntu.edu.cn.
² Institute of Modern Rehabilitation, University of Health and Rehabilitation Science Qingdao 266001 China jfyang@uor.edu.cn.

Abstract

Since the outbreak of COVID-19, the pandemic caused by SARS-CoV-2 infection is still spreading at an alarming rate and has caused huge loss of life and economic damage worldwide. Although more than one year has passed, effective treatments for COVID-19 and other pathogenic coronaviruses have not yet been developed. Therefore, the development of SARS-CoV-2 inhibitors is an urgent priority. Given that the M^pro sequences of SARS-CoV-2 and SARS-CoV-1 are 100% identical in the catalytic domain for protein cleavage, the viral main protease (M^pro) is one of the most extensive drug targets in all the drug targets being investigated for SARS-CoV-2. To provide scientific researchers with timely anti-SARS-CoV drug development information for M^pro, we focus on the past and current drug design and development strategies for M^Pro in this review. We believe that this review will provide meaningful guidance for the design and development of innovative drugs against COVID-19 and other pathogenic coronaviruses in the future.

Publication types

Review